Opinion

The publication's June installment features a plethora of coverage, ranging from the learning curve in digital adoption to an overview of the CVD market.

As the brand looks to increase its coverage, Pharma Commerce welcomes a pair of editorial contributors to the team.

Although there is no ‘one size fits all’ solution, the process is influenced by factors such as lifestyle stage, competitive outlook, and market constraints.

DSCSA, 340B among the headliners at the Healthcare Distribution Alliance's Distribution Management Conference.

How molding these elements into one can add efficiencies to work processes.

Why automation-enabling tech—such as NLP and ML—can help improve medicine effectiveness.

Senate committee report highlights a lack of visibility in API suppliers.

Pharma Commerce provides a look into a few of the conference’s highlights.

Event—taking place in Indianapolis—places supply chain education at the forefront.

A multitude of conclusions surrounding distribution were reached at the Trade & Channels Strategies conference.

Observations from recent digital health events and a glimpse of what’s ahead—from Milan to Boca Raton

Companies along the pharma value chain strive for carbon neutrality

How artificial intelligence is improving the patient experience

Product commercialization in Canada is by no means simple, but the end result presents its advantages

Decision-making technologies come to the forefront of the AI space

How pharma can speed up the journey with direct-to-patient models

Pharma Commerce's podcasts offer new angles on its roster of key topics

Given the biopharma sector‘s complex set of networks and supply chains, so it is not straightforward to shift towards net zero across all operations.

Dr. Frank Doyle, Dean of the Paulson School of Engineering and Applied Sciences at Harvard University, outlines his recommendations for Fortune 500 c-suites as they strive to attract, develop, and retain the best talent for their upcoming 2023 strategic plans.

A reflection on the industry's effort to foster and facilitate sustainability

EVERSANA CEO Jim Lang discusses the organization’s continuing rise in an industry that has seen seismic changes taking place

PC's new editor-in-chief details his thought process on familiarizing himself with a different side of the industry

It's time to include hubs in the patient treatment journey

How CDMOs will lead the way toward true cloud lab enablement

Harvard Business School Professor Amy C. Edmondson talks about achieving psychological safety in the workplace.

From supply-chain and clinical-trial disruptions in Ukraine and Russia, to decisions to halt investment or maintain operations, global implications for industry and pharmaceutical production are immense.

The life sciences industry is at an inflection point, with pressures around pricing, patient access, and affordability converging with the cost of increasingly complex and personalized medicines to make today’s economics unsustainable. Scott Howell and Ray Pressburger discuss what can be done to help solve these challenges across the industry.

Introducing our first deep dive into pharma's indispensable partner—the 3PL

Can technology really build trust in pharmaceutical supply chains?

A prescription for making the pharma supply chain more resilient, reliable and disruption-proof